Impaired glucose metabolism and other metabolic disorders in patients with primary hyperparathyroidism
Ekaterina E. Bibik,
[Anna K. Eremkina,
Julia A. Krupinova,
Natalia V. Klementieva,
Ekaterina A. Dobreva,
Natalia G. Mokrysheva https://doi.org/10.14341/DM12436
Abstract
The clinical picture of primary hyperparathyroidism (PHPT) which caused by parathyroid neoplasms often includes metabolic syndrome leading to the development of cardiovascular diseases. According to clinical studies, an increased incidence of diabetes mellitus, insulin resistance, obesity, dyslipidemia, hyperuricemia and other disorders that signifi tly affect the life span and quality are observed in patients with PHPT regardless of the form and the severity of the underlying disease. Basic research shows the potential nonclassical effects of high levels of parathyroid hormone and calcium on adipose tissue, pancreas, gastrointestinal tract and kidneys. However, the pathogenetic mechanisms of impaired carbohydrate and other types of metabolism in patients with parathyroid hyperfunction remain unclear because of the lack of relevant experimental models and the heterogeneity of patient groups. Besides, the effect of surgery on metabolic abnormalities is also controversial. Nowadays a deeper understanding of this issue is required, which can subsequently help in the creation of optimal approach to diagnosis and treatment of patients. This review covers different aspects of metabolic disorders in patients with PHPT, as well as potential key factors of their development.
About the Authors
Ekaterina E. Bibik
Endocrinology Research Centre
Russian Federation
Russian Federation
MD
eLibrary SPIN: 8522-9466
11 Dm. Ulyanova street, 117036 Moscow
[Anna K. Eremkina
Endocrinology Research Centre
Russian Federation
Russian Federation
MD, PhD
eLibrary SPIN: 8848-2660
Moscow
Julia A. Krupinova
Endocrinology Research Centre
Russian Federation
Russian Federation
MD
eLibrary SPIN: 6279-8247
Moscow
Natalia V. Klementieva
Endocrinology Research Centre
Russian Federation
Russian Federation
PhD in Biology
eLibrary SPIN: 5318-3774
Moscow
Ekaterina A. Dobreva
Endocrinology Research Centre
Russian Federation
Russian Federation
MD, PhD
eLibrary SPIN: 3405-2467
Moscow
Natalia G. Mokrysheva
Endocrinology Research Centre
Russian Federation
Russian Federation
MD, PhD, Professor
eLibrary SPIN: 5624-3875
Moscow
References
1. Procopio M, Barale M, Bertaina S, et al. Cardiovascular risk and metabolic syndrome in primary hyperparathyroidism and their correlation to different clinical forms. Endocrine. 2014;47(2):581-589. https://doi.org/10.1007/s12020-013-0091-z
2. Ljunghall S, Palmer M, Akerstrom G, Wide L. Diabetes mellitus, glucose tolerance and insulin response to glucose in patients with primary hyperparathyroidism before and after parathyroidectomy. Eur J Clin Invest. 1983;13(5):373-377. https://doi.org/10.1111/j.1365-2362.1983.tb00116.x
3. Mokrysheva NG, Dobreva EA, Mirnaya SS, Dedov II. Carbohydrate and lipid metabolism disorders in women with primary hyperparathyroidism: results of cross-sectional study. Diabetes mellitus. 2019;22(1):8-13. (In Russ.). https://doi.org/10.14341/DM9450
4. Procopio M, Borretta G. Derangement of glucose metabolism in hyperparathyroidism. J Endocrinol Invest. 2003;26(11):1136-1142. https://doi.org/10.1007/BF03345264
5. Tassone F, Maccario M, Gianotti L, et al. Insulin sensitivity in normocalcaemic primary hyperparathyroidism. Endocrine. 2013;44(3):812-814. https://doi.org/10.1007/s12020-013-0059-z
6. Temizkan S, Kocak O, Aydin K, et al. Normocalcemic hyperparathyroidism and insulin resistance. Endocr Pract. 2015;21(1):23-29. https://doi.org/10.4158/EP14195.OR
7. Tassone F, Procopio M, Gianotti L, et al. Insulin resistance is not coupled with defective insulin secretion in primary hyperparathyroidism. Diabet Med. 2009;26(10):968-973. https://doi.org/10.1111/j.1464-5491.2009.02804.x
8. Kim H, Kalkhoff RK, Costrini NV, et al. Plasma insulin disturbances in primary hyperparathyroidism. J Clin Invest. 1971;50(12):2596-2605. https://doi.org/10.1172/JCI106760
9. Sun G, Vasdev S, Martin GR, et al. Altered calcium homeostasis is correlated with abnormalities of fasting serum glucose, insulin resistance, and beta-cell function in the Newfoundland population. Diabetes. 2005;54(11):3336-3339. https://doi.org/10.2337/diabetes.54.11.3336
10. Babinsky VN, Hannan FM, Ramracheya RD, et al. Mutant Mice With Calcium-Sensing Receptor Activation Have Hyperglycemia That Is Rectified by Calcilytic Therapy. Endocrinology. 2017;158(8):2486-2502. https://doi.org/10.1210/en.2017-00111
11. Hagstrom E, Hellman P, Lundgren E, et al. Serum calcium is independently associated with insulin sensitivity measured with euglycaemic-hyperinsulinaemic clamp in a community-based cohort. Diabetologia. 2007;50(2):317-324. https://doi.org/10.1007/s00125-006-0532-9
12. Haap M, Heller E, Thamer C, et al. Association of serum phosphate levels with glucose tolerance, insulin sensitivity and insulin secretion in non-diabetic subjects. Eur J Clin Nutr. 2006;60(6):734-739. https://doi.org/10.1038/sj.ejcn.1602375
13. Harter HR, Santiago J V, Rutherford WE, et al. The relative roles of calcium, phosphorus, and parathyroid hormone in glucoseand tolbutamide-mediated insulin release. J Clin Invest. 1976;58(2):359-367. https://doi.org/10.1172/JCI108480
14. Reis JP, Selvin E, Pankow JS, et al. Parathyroid hormone is associated with incident diabetes in white, but not black adults: The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Metab. 2016;42(3):162-169. https://doi.org/10.1016/j.diabet.2015.12.004
15. Chang E, Donkin SS, Teegarden D. Parathyroid hormone suppresses insulin signaling in adipocytes. Mol Cell Endocrinol. 2009;307(1-2):77-82. https://doi.org/10.1016/j.mce.2009.03.024
16. Thomas DM, Rogers SD, Sleeman MW, et al. Modulation of glucose transport by parathyroid hormone and insulin in UMR 106-01, a clonal rat osteogenic sarcoma cell line. J Mol Endocrinol. 1995;14(2):263-275. https://doi.org/10.1677/jme.0.0140263
17. Reusch JE, Begum N, Sussman KE, Draznin B. Regulation of GLUT-4 phosphorylation by intracellular calcium in adipocytes. Endocrinology. 1991;129(6):3269-3273. https://doi.org/10.1210/endo-129-6-3269
18. Kanazawa I. Interaction between bone and glucose metabolism [Review]. Endocr J. 2017;64(11):1043-1053. https://doi.org/10.1507/endocrj.EJ17-0323
19. Bao Y, Ma X, Yang R, et al. Inverse relationship between serum osteocalcin levels and visceral fat area in Chinese men. J Clin Endocrinol Metab. 2013;98(1):345-351. https://doi.org/10.1210/jc.2012-2906
20. Gianotti L, Piovesan A, Croce CG, et al. Interplay between serum osteocalcin and insulin sensitivity in primary hyperparathyroidism. Calcif Tissue Int. 2011;88(3):231-237. https://doi.org/10.1007/s00223-010-9453-1
21. Mendonca ML, Batista SL, Nogueira-Barbosa MH, et al. Primary Hyperparathyroidism: The Influence of Bone Marrow Adipose Tissue on Bone Loss and of Osteocalcin on Insulin Resistance. Clinics (Sao Paulo). 2016;71(8):464-469. https://doi.org/10.6061/clinics/2016(08)09
22. Putnam R, Dhibar DP, Varshney S, et al. Effect of curative parathyroidectomy on insulin resistance. Indian J Endocrinol Metab. 2016;20(6):784-789. https://doi.org/10.4103/2230-8210.192916
23. Bhadada SK, Bhansali A, Shah VN, Rao DS. Changes in serum leptin and adiponectin concentrations and insulin resistance after curative parathyroidectomy in moderate to severe primary hyperparathyroidism. Singapore Med J. 2011;52(12):890-893.
24. Bergenfelz A, Bladstrom A, Their M, et al. Serum levels of uric acid and diabetes mellitus influence survival after surgery for primary hyperparathyroidism: a prospective cohort study. World J Surg. 2007;31(7):1392-1393. https://doi.org/10.1007/s00268-007-9091-6
25. Kautzky-Willer A, Pacini G, Niederle B, et al. Insulin secretion, insulin sensitivity and hepatic insulin extraction in primary hyperparathyroidism before and after surgery. Clin Endocrinol (Oxf). 1992;37(2):147-155. https://doi.org/10.1111/j.1365-2265.1992.tb02299.x
26. Cvijovic G, Micic D, Kendereski A, et al. The effect of parathyroidectomy on insulin sensitivity in patients with primary hyperparathyroidism — an never ending story? Exp Clin Endocrinol Diabetes. 2015;123(6):336-341. https://doi.org/10.1055/s-0035-1549906
27. Prager R, Schernthaner G, Niederle B, Roka R. Evaluation of glucose tolerance, insulin secretion, and insulin action in patients with primary hyperparathyroidism before and after surgery. Calcif Tissue Int. 1990;46(1):1-4. https://doi.org/10.1007/bf02555816
28. Antonopoulou V, Karras SN, Koufakis T, et al. Rising Glucagon-Like Peptide 1 Concentrations After Parathyroidectomy in Patients With Primary Hyperparathyroidism. J Surg Res. 2020;245:22-30. https://doi.org/10.1016/j.jss.2019.07.019
29. McCallum RW, Parameswaran V, Burgess JR. Multiple endocrine neoplasia type 1 (MEN 1) is associated with an increased prevalence of diabetes mellitus and impaired fasting glucose. Clin Endocrinol (Oxf). 2006;65(2):163-168. https://doi.org/10.1111/j.1365-2265.2006.02563.x
30. van Wijk JPH, Dreijerink KMA, Pieterman CRC, et al. Increased prevalence of impaired fasting glucose in MEN1 gene mutation carriers. Clin Endocrinol (Oxf). 2012;76(1):67-71. https://doi.org/10.1111/j.1365-2265.2011.04166.x
31. Grey AB, Evans MC, Stapleton JP, Reid IR. Body weight and bone mineral density in postmenopausal women with primary hyperparathyroidism. Ann Intern Med. 1994;121(10):745-749. https://doi.org/10.7326/0003-4819-121-10-199411150-00003
32. Bolland MJ, Grey AB, Gamble GD, Reid IR. Association between primary hyperparathyroidism and increased body weight: a meta-analysis. J Clin Endocrinol Metab. 2005;90(3):1525-1530. https://doi.org/10.1210/jc.2004-1891
33. Mokrysheva NG. Pervichnyi giperparatireoz. Epidemiologgiya, klinika, sovremennye princypy diagnostiki i lecheniya. [dissertation]. M., 2011. (In Russ.). Доступно по: https://dlib.rsl.ru/01005084680
34. McCarty MF, Thomas CA. PTH excess may promote weight gain by impeding catecholamine-induced lipolysisimplications for the impact of calcium, vitamin D, and alcohol on body weight. Med Hypotheses. 2003;61(5-6):535-542. https://doi.org/10.1016/s0306-9877(03)00227-5
35. Fan Y, Hanai J-I, Le PT, et al. Parathyroid Hormone Directs Bone Marrow Mesenchymal Cell Fate. Cell Metab. 2017;25(3):661-672. https://doi.org/10.1016/j.cmet.2017.01.001
36. Bravo-Sagua R, Mattar P, Díaz X, et al. Calcium Sensing Receptor as a Novel Mediator of Adipose Tissue Dysfunction: Mechanisms and Potential Clinical Implications. Front Physiol. 2016;7:395. https://doi.org/10.3389/fphys.2016.00395
37. Christensen MHE, Dankel SN, Nordbø Y, et al. Primary Hyperparathyroidism Influences the Expression of Inflammatory and Metabolic Genes in Adipose Tissue. Oresic M, ed. PLoS One. 2011;6(6):e20481. https://doi.org/10.1371/journal.pone.0020481
38. Delfi E, Petramala L, Caliumi C, et al. Circulating leptin and adiponectin levels in patients with primary hyperparathyroidism. Metabolism. 2007;56(1):30-36. https://doi.org/10.1016/j.metabol.2006.08.019
39. Matsunuma A, Horiuchi N. Leptin attenuates gene expression for renal 25-hydroxyvitamin D3-1alpha-hydroxylase in mice via the long form of the leptin receptor. Arch Biochem Biophys. 2007;463(1):118-127. https://doi.org/10.1016/j.abb.2007.02.031
40. Grethen E, Hill KM, Jones R, et al. Serum leptin, parathyroid hormone, 1,25-dihydroxyvitamin D, fi oblast growth factor 23, bone alkaline phosphatase, and sclerostin relationships in obesity. J Clin Endocrinol Metab. 2012;97(5):1655-1662. https://doi.org/10.1210/jc.2011-2280
41. Hoang D, Broer N, Sosa JA, et al. Leptin Is Produced by Parathyroid Glands and Stimulates Parathyroid Hormone Secretion. Ann Surg. 2017;266(6):1075-1083. https://doi.org/10.1097/SLA.0000000000002004
42. Raghay K, García-Caballero T, Nogueiras R, et al. Ghrelin localization in rat and human thyroid and parathyroid glands and tumours. Histochem Cell Biol. 2006;125(3):239-246. https://doi.org/10.1007/s00418-005-0044-6
43. Yamamoto K, Isogai Y, Ishida T, Hagihara K. Enhancement of ghrelin-signaling system by Rikkunshi-To attenuates teriparatideinduced pica in rats. J Pharmacol Sci. 2018;137(2):137-145. https://doi.org/10.1016/j.jphs.2018.05.003
44. Adam MA, Untch BR, Danko ME, et al. Severe obesity is associated with symptomatic presentation, higher parathyroid hormone levels, and increased gland weight in primary hyperparathyroidism. J Clin Endocrinol Metab. 2010;95(11):4917-4924. https://doi.org/10.1210/jc.2010-0666
45. Kuo LE, Wachtel H, Fraker D, Kelz R. Reoperative parathyroidectomy: who is at risk and what is the risk? J Surg Res. 2014;191(2):256-261. https://doi.org/10.1016/j.jss.2014.05.073
46. Hedesan OC, Fenzl A, Digruber A, et al. Parathyroid hormone induces a browning program in human white adipocytes. Int J Obes (Lond). 2019;43(6):1319-1324. https://doi.org/10.1038/s41366-018-0266-z
47. He Y, Liu R-X, Zhu M-T, et al. The browning of white adipose tissue and body weight loss in primary hyperparathyroidism. EBioMedicine. 2019;40:56-66. https://doi.org/10.1016/j.ebiom.2018.11.057
48. Wannamethee SG, Welsh P, Papacosta O, et al. Elevated parathyroid hormone, but not vitamin D deficiency, is associated with increased risk of heart failure in older men with and without cardiovascular disease. Circ Heart Fail. 2014;7(5):732-739 https://doi.org/10.1161/CIRCHEARTFAILURE.114.001272
49. Querfeld U, Hoffmann MM, Klaus G, et al. Antagonistic effects of vitamin D and parathyroid hormone on lipoprotein lipase in cultured adipocytes. J Am Soc Nephrol. 1999;10(10):2158-2164.
50. Hagstrom E, Lundgren E, Lithell H, et al. Normalized dyslipidaemia after parathyroidectomy in mild primary hyperparathyroidism: population-based study over five years. Clin Endocrinol (Oxf). 2002;56(2):253-260. https://doi.org/10.1046/j.0300-0664.2001.01468.x
51. Hagstrom E, Lundgren E, Rastad J, Hellman P. Metabolic abnormalities in patients with normocalcemic hyperparathyroidism detected at a population-based screening. Eur J Endocrinol. 2006;155(1):33-39. https://doi.org/10.1530/eje.1.02173
52. Beysel S, Caliskan M, Kizilgul M, et al. Parathyroidectomy improves cardiovascular risk factors in normocalcemic and hypercalcemic primary hyperparathyroidism. BMC Cardiovasc Disord. 2019;19(1):106. https://doi.org/10.1186/s12872-019-1093-4
53. Godang K, Lundstam K, Mollerup C, et al. The effect of surgery on fat mass, lipid and glucose metabolism in mild primary hyperparathyroidism. Endocr Connect. 2018;7(8):941-948. https://doi.org/10.1530/EC-18-0259
54. Ponvilawan B, Charoenngam N, Ungprasert P. Primary hyperparathyroidism is associated with a higher level of serum uric acid: A systematic review and meta-analysis. Int J Rheum Dis. 2020;23(2):174-180. https://doi.org/10.1111/1756-185X.13740
55. Paik JM, Farwell WR, Taylor EN. Demographic, dietary, and serum factors and parathyroid hormone in the National Health and Nutrition Examination Survey. Osteoporos Int. 2012;23(6):1727-1736. https://doi.org/10.1007/s00198-011-1776-x
56. Sugimoto R, Watanabe H, Ikegami K, et al. Downregulation of ABCG2, a urate exporter, by parathyroid hormone enhances urate accumulation in secondary hyperparathyroidism. Kidney Int. 2017;91(3):658-670. https://doi.org/10.1016/j.kint.2016.09.041
57. Girardi AC, Titan SM, Malnic G, Reboucas NA. Chronic effect of parathyroid hormone on NHE3 expression in rat renal proximal tubules. Kidney Int. 2000;58(4):1623-1631. https://doi.org/10.1046/j.1523-1755.2000.00323.x
58. Carroll R, Matfin G. Endocrine and metabolic emergencies:hypercalcaemia. Ther Adv Endocrinol Metab. 2010;1(5):225-234. https://doi.org/10.1177/2042018810390260
59. Christensson T. Serum urate in subjects with hypercalcaemic hyperparathyroidism. Clin Chim Acta. 1977;80(3):529-533. https://doi.org/10.1016/0009-8981(77)90147-4
60. Yoneda M, Takatsuki K, Tomita A. [Parathyroid function and uric acid metabolism]. Nihon Naibunpi Gakkai Zasshi. 1983;59(11):1738-1751. https://doi.org/10.1507/endocrine1927.59.11_1738
Supplementary files
Review
For citations:
Bibik E.E., Eremkina [.K., Krupinova J.A., Klementieva N.V., Dobreva E.A., Mokrysheva N.G. Impaired glucose metabolism and other metabolic disorders in patients with primary hyperparathyroidism. Diabetes mellitus. 2020;23(5):459-466. (In Russ.) https://doi.org/10.14341/DM12436
Views:
1756
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
